Correction to: Adv Ther (2022) 39:1895–1914 https://doi.org/10.1007/s12325-022-02092-7

The authors would like to highlight an error in Fig. 3 of the original publication. The solid black symbols in Fig. 3 were incorrectly labelled with “BUD/FOR 200/6 µg” but should instead be labelled with “BUD 200 µg”. The updated Fig. 3 is included herein.

Fig. 3
figure 3

Comparison of airway efficacy to systemic activity for BUD/FOR as-needed and regular ICS dosing regimens in mild asthma. Superscript numbers correspond to source references from the original publication as follows: 8. Bateman ED, et al. N Engl J Med. 2018;378(20):1877–87; 9. Beasley R, et al. N Engl J Med. 2019;380(21):2020–30; 10. Hardy J, et al. Lancet. 2019;394(10202):919–28; 11. O’Byrne PM, et al. N Engl J Med. 2018;378(20):1865–76. AEF airway efficacy, BID twice daily, BUD budesonide, DD doubling dose, FOR formoterol, FP fluticasone propionate, ICS inhaled corticosteroid, PRN as needed, SA systemic activity